Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

14,863 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Donor-Derived CD7 Chimeric Antigen Receptor T Cells for T-Cell Acute Lymphoblastic Leukemia: First-in-Human, Phase I Trial.
Pan J, Tan Y, Wang G, Deng B, Ling Z, Song W, Seery S, Zhang Y, Peng S, Xu J, Duan J, Wang Z, Yu X, Zheng Q, Xu X, Yuan Y, Yan F, Tian Z, Tang K, Zhang J, Chang AH, Feng X. Pan J, et al. Among authors: tan y. J Clin Oncol. 2021 Oct 20;39(30):3340-3351. doi: 10.1200/JCO.21.00389. Epub 2021 Jul 29. J Clin Oncol. 2021. PMID: 34324392 Clinical Trial.
Ruxolitinib mitigates steroid-refractory CRS during CAR T therapy.
Pan J, Deng B, Ling Z, Song W, Xu J, Duan J, Wang Z, Chang AH, Feng X, Tan Y. Pan J, et al. Among authors: tan y. J Cell Mol Med. 2021 Jan;25(2):1089-1099. doi: 10.1111/jcmm.16176. Epub 2020 Dec 12. J Cell Mol Med. 2021. PMID: 33314568 Free PMC article. Clinical Trial.
A novel full-human CD22-CAR T cell therapy with potent activity against CD22low B-ALL.
Tan Y, Cai H, Li C, Deng B, Song W, Ling Z, Hu G, Yang Y, Niu P, Meng G, Cheng W, Xu J, Duan J, Wang Z, Yu X, Feng X, Zhou J, Pan J. Tan Y, et al. Blood Cancer J. 2021 Apr 10;11(4):71. doi: 10.1038/s41408-021-00465-9. Blood Cancer J. 2021. PMID: 33839735 Free PMC article. Clinical Trial. No abstract available.
Sequential CD19 and CD22 chimeric antigen receptor T-cell therapy for childhood refractory or relapsed B-cell acute lymphocytic leukaemia: a single-arm, phase 2 study.
Pan J, Tang K, Luo Y, Seery S, Tan Y, Deng B, Liu F, Xu X, Ling Z, Song W, Xu J, Duan J, Wang Z, Li C, Wang K, Zhang Y, Yu X, Zheng Q, Zhao L, Zhang J, Chang AH, Feng X. Pan J, et al. Among authors: tan y. Lancet Oncol. 2023 Nov;24(11):1229-1241. doi: 10.1016/S1470-2045(23)00436-9. Epub 2023 Oct 17. Lancet Oncol. 2023. PMID: 37863088 Clinical Trial.
Allogeneic CD5-specific CAR-T therapy for relapsed/refractory T-ALL: a phase 1 trial.
Pan J, Tan Y, Shan L, Seery S, Deng B, Ling Z, Xu J, Duan J, Wang Z, Wang K, Yu X, Zheng Q, Xu X, Hu G, Tan T, Yuan Y, Tian Z, Yan F, Han Y, Zhang J, Feng X. Pan J, et al. Among authors: tan t, tan y. Nat Med. 2024 Oct 1. doi: 10.1038/s41591-024-03282-2. Online ahead of print. Nat Med. 2024. PMID: 39354195
14,863 results
You have reached the last available page of results. Please see the User Guide for more information.